- Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal
- The extract, Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10, is now approved for medical use in Portugal
- This follows the approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year
- Tilray stock last traded at C$2.60 per share
Tilray Medical, a subsidiary of Tilray Brands (TSX:TLRY) has been approved for a new medical cannabis extract in Portugal.
The extract, Tilray Oral Solution THC10:CBD10, also known as Tilray Solução Oral THC10:CBD10, is now approved for medical use in Portugal.
“This is a significant step towards meeting the critical needs of patient care and providing high-quality cannabis products and therapeutic options to those with specific medical conditions,” Tilray’s head of international and chief strategy officer, Denise Faltischek, said in a news release. “The approval of this oral cannabis solution in Portugal is a testament to Tilray’s global commitment to increasing safe and regulated access to medical cannabis products for patients in need.”
This follows the approval of Tilray Medical whole flower THC 18, and approval for the first cannabis extract in Portugal earlier this year.
Tilray is a global cannabis and consumer packaged goods company managing more than 20 brands in more than 20 countries, including Broken Coast, Redecan and Good Supply. Tilray Medical has operations in more than 20 countries, having grown from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe.
Tilray stock (TSX:TLRY) last traded at C$2.60 per share. The stock has grown 17.12 per cent year-over-year but lost 86.77 per cent over the past five years.
Join the discussion: Find out what everybody’s saying about this cannabis stock on the Tilray Brands Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Tilray Medical)